{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:16:45Z","timestamp":1782253005897,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/bf03261935","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T19:58:44Z","timestamp":1356811124000},"page":"619-628","source":"Crossref","is-referenced-by-count":32,"title":["Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function"],"prefix":"10.1007","volume":"51","author":[{"given":"Michelle","family":"Treitel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Feely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"O\u2019Mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kasserra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"1935_CR1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","volume":"50","author":"B.A. Malcolm","year":"2006","unstructured":"Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50: 1013\u201320","journal-title":"Antimicrob Agents Chemother"},{"key":"1935_CR2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"P.Y. Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treat-ment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705\u201316","journal-title":"Lancet"},{"key":"1935_CR3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"B. Bacon","year":"2011","unstructured":"Bacon B, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207\u201317","journal-title":"N Engl J Med"},{"key":"1935_CR4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F. Poordad","year":"2011","unstructured":"Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195\u2013206","journal-title":"N Engl J Med"},{"key":"1935_CR5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/hep.22165","volume":"47","author":"M. Wise","year":"2008","unstructured":"Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995\u20132004. Hepatology 2008; 47: 1128\u201335","journal-title":"Hepatology"},{"issue":"3","key":"1935_CR6","first-page":"S10","volume":"9","author":"R.S. Brown Jr","year":"2003","unstructured":"Brown Jr RS, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transplant 2003; 9 Suppl. 3: S10\u20133","journal-title":"Liver Transplant"},{"key":"1935_CR7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","volume":"39","author":"A. Ghosal","year":"2011","unstructured":"Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a HCV protease inhibitor. Drug Metab Pharmacokinet 2011; 39: 510\u201321","journal-title":"Drug Metab Pharmacokinet"},{"key":"1935_CR8","unstructured":"Victrelis\u2122 (boceprevir) [prescribing information]. Whitehouse Station (NJ): Schering Corporation, a subsidiary of Merck & Co., Inc., 2011"},{"key":"1935_CR9","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. US Food and Drug Administration Web site: 1\u201316 [online]. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072123.pdf [Accessed 2012 Feb 12]"},{"key":"1935_CR10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"R.N.H. Pugh","year":"1973","unstructured":"Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646\u20139","journal-title":"Br J Surg"},{"key":"1935_CR11","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.jchromb.2009.10.013","volume":"877","author":"H. Farnik","year":"2009","unstructured":"Farnik H, El-Duweik J, Welsch C, et al. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 4001\u20136","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1935_CR12","unstructured":"Data on file, Merck, 2010"},{"key":"1935_CR13","unstructured":"Peglntron\u2122 (peginterferon alfa-2b) [prescribing information]. Kenilworth (NJ): Schering Corporation, 2008 Mar"},{"key":"1935_CR14","unstructured":"Rebetol\u00ae (ribavirin UPS) capsules, oral solution [prescribing information]. Kenilworth (NJ): Schering Corporation, 2009 Nov"},{"key":"1935_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","volume":"36","author":"F. Fabrizi","year":"2002","unstructured":"Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3\u201310","journal-title":"Hepatology"},{"key":"1935_CR16","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2007.01.041","volume":"132","author":"C. Sarrazin","year":"2007","unstructured":"Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha 2b for genotype 1 non-responders. Gastroenterology 2007; 132: 1270\u20138","journal-title":"Gastroenterology"},{"key":"1935_CR17","unstructured":"Data on file, Merck, 2008"},{"key":"1935_CR18","unstructured":"Data on file, Merck, 2007"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261935.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03261935\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T01:41:48Z","timestamp":1558489308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03261935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1935"],"URL":"https:\/\/doi.org\/10.1007\/bf03261935","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}